Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027

Fulcrum Therapeutics, Inc.

2024-FY EPS reported -$0.16 revenue$80,000,000

Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.
Cash and marketable securities $241.0M as of Dec 31, 2024, sufficient into at least 2027.
Phase 1b PIONEER trial of pociredir in SCD: 10 patients enrolled in 12 mg cohort; data expected mid-2025.
Plan to submit IND for Diamond-Blackfan anemia program in Q4 2025.
Phase 3 REACH trial (losmapimod) data to be presented at MDA Conference on March 19, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.